Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Eli Lilly Q2 2024 Earnings Highlights: Exceptional Growth Driven by New Products

by Team Lumida
August 10, 2024
in Equities
Reading Time: 9 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Eli Lilly delivered exceptional Q2 2024 results, with revenue growth of 36% driven by strong performance of new products, particularly Mounjaro and Zepbound.

Top Takeaways

  1. Revenue grew 36% in Q2, with new products contributing nearly $3.5 billion in growth compared to the same period last year.
  2. Mounjaro and Zepbound sales exceeded expectations, with combined U.S. sales of $3.6 billion in Q2.
  3. Lilly raised full-year revenue guidance by $3 billion, reflecting strong performance and increased confidence in production expansion.
  4. The company received FDA approval for Kisunla (donanemab) for Alzheimer’s disease treatment.
  5. Lilly is investing heavily in manufacturing expansion, committing over $18 billion since 2020 to build, upgrade, or acquire facilities in the U.S. and Europe.

Summary

Eli Lilly’s Q2 2024 performance was marked by accelerated growth, with revenue increasing 36% to $45.4-$46.6 billion. The company’s new products, particularly Mounjaro and Zepbound, drove this exceptional growth. CEO Dave Ricks highlighted the company’s progress:

“It’s an exciting time here at Lilly as our growth trajectory accelerated in the second quarter. Our investments in advancing innovative medicine are focused on manufacturing expansion are bringing Lilly medicines to more people around the world.”

Main Themes

  • Guidance: Full-year revenue outlook raised by $3 billion to $45.4-$46.6 billion
  • New Product Announcements: FDA approval of Kisunla for Alzheimer’s disease treatment
  • Manufacturing Expansion: $18 billion committed since 2020 for facility upgrades and acquisitions
  • Pipeline Progress: Positive Phase 3 results for tirzepatide in heart failure and obesity
  • Market Opportunity: Expanding presence in obesity and diabetes markets globally

Insights

Lilly’s strategy in the obesity market is comprehensive, addressing multiple mechanisms, indications, and dosage forms. The company now has 11 new molecules in clinical trials across various indications, demonstrating its commitment to this growing market segment.

Market Opportunity

Lilly is targeting the global obesity market, which represents a significant growth opportunity. The company is expanding its presence in international markets, with Mounjaro launches progressing well in countries like the UK, Germany, and UAE. The addressable market for obesity treatments is expanding as more employers opt into coverage for these medications.

Market Commentary

The obesity treatment market is experiencing rapid growth and increased competition. Lilly is positioning itself as a leader in this space through its comprehensive approach to drug development and manufacturing expansion. The company’s focus on multiple mechanisms and formulations (oral and injectable) aims to address various patient needs and preferences.

Customer Behaviors

Patient demand for Mounjaro and Zepbound remains strong and growing. Lilly is working to improve patient persistence with therapy by enhancing consumer platforms and digital channels. The company is also engaging with employers to communicate the broader health and productivity benefits of obesity treatments.

Capex

Lilly announced an additional $5.3 billion investment in its Lebanon, Indiana manufacturing site, bringing the total investment there to $9 billion. This expansion will enhance capacity to manufacture active pharmaceutical ingredients for Zepbound and Mounjaro.

Regulatory Policy

Lilly received FDA approval for Kisunla (donanemab) for Alzheimer’s disease treatment. The approval includes labeling that allows physicians to consider stopping dosing based on reduction of amyloid plaques, potentially leading to lower treatment costs and fewer infusions required.

Economy Insights

While specific economic commentary was limited, Lilly’s strong performance and increased guidance suggest resilient demand for its products despite broader economic uncertainties.

Industry Insights

Lilly’s success in the obesity and diabetes markets may have positive implications for other players in the pharmaceutical industry focused on these therapeutic areas. The company’s manufacturing expansion efforts highlight the importance of robust supply chains in meeting growing demand for innovative treatments.

Key Metrics

Financial Metrics

  • Revenue growth: 36% YoY
  • U.S. revenue growth: 42% YoY
  • Operating income increase: 90% YoY
  • Earnings per share: $3.92, up 86% YoY

KPIs

  • Mounjaro global sales: $3.1 billion
  • Zepbound U.S. sales: Over $1.2 billion
  • Verzenio sales growth: 44% YoY
  • Commercial access for Zepbound: 86% as of July 1

Competitive Differentiators

  1. Comprehensive obesity treatment portfolio with 11 molecules in clinical trials
  2. Strong manufacturing capabilities and ongoing expansion efforts
  3. Multiple formulations (oral and injectable) addressing various patient needs
  4. Robust pipeline across multiple therapeutic areas
  5. Successful launch and rapid uptake of new products like Mounjaro and Zepbound

Key Risks

  1. Potential supply constraints due to high demand for incretin medicines
  2. Increasing competition in the obesity and diabetes markets
  3. Regulatory challenges and potential pricing pressures
  4. Dependence on key products for growth
  5. Manufacturing and supply chain complexities

Analyst Q&A Focus Areas

Analysts focused on:

  1. Pricing dynamics and average selling prices for incretin medicines
  2. Manufacturing capacity and supply chain challenges
  3. Differentiation strategies for oral obesity treatments
  4. Ex-U.S. market opportunities and reimbursement landscape
  5. Potential for muscle-preserving obesity drugs

Eli Lilly Summary:

Eli Lilly’s exceptional Q2 2024 performance demonstrates the company’s strong position in the rapidly growing obesity and diabetes markets. With significant investments in manufacturing capacity, a robust pipeline, and successful new product launches, Lilly is well-positioned for continued growth. Investors should watch for further developments in the company’s obesity treatment portfolio, international market expansions, and progress in addressing supply chain challenges to meet the growing demand for its innovative medicines.

Tags: EARNINGSEliLilly
Previous Post

Bumble Inc. Q2 2024 Earnings Highlights: Strategic Reset Amid Growth Challenges

Next Post

Cheniere Energy Q2 2024 Earnings Highlights: Exceeding Expectations and Raising Guidance

Recommended For You

Corporate Pension Funds Shift Strategies Amid Full Funding, Impacting Bonds and Private Equity

by Team Lumida
7 hours ago
a computer screen with a bunch of data on it

Key Takeaways: Powered by lumidawealth.com Corporate pension funds, with over $3 trillion in assets, have reached a healthier financial state, with the largest 100 U.S. corporate pensions achieving a...

Read more

Costco Mitigates Tariff Impact Through Strategic Sourcing and Order Advancements

by Team Lumida
2 days ago
Costco Mitigates Tariff Impact Through Strategic Sourcing and Order Advancements

Key Takeaways: Powered by lumidawealth.com Costco is reducing tariff exposure by pulling orders forward and shifting private-label product sourcing to regions where they are sold, helping to control costs...

Read more

Salesforce Raises Full-Year Sales Outlook as AI Drives Growth

by Team Lumida
3 days ago
Salesforce Raises Full-Year Sales Outlook as AI Drives Growth

Key Takeaways: Powered by lumidawealth.com Salesforce’s Q1 revenue rose 8% year-over-year to $9.83 billion, beating Wall Street expectations of $9.75 billion. Adjusted earnings per share were $2.58, exceeding the...

Read more

Global Markets Mixed as Investors Await Nvidia Earnings and Monitor Rising Bond Yields

by Team Lumida
4 days ago
Global Markets Mixed as Investors Await Nvidia Earnings and Monitor Rising Bond Yields

Key Takeaways: Powered by lumidawealth.com U.S. stock futures pointed to a slightly weaker open, with the S&P 500 futures down 0.1% and Nasdaq futures flat ahead of Nvidia’s earnings...

Read more

Markets Hold $7 Trillion in Cash Ahead of Nvidia Earnings, Eyeing AI Demand

by Team Lumida
5 days ago
Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Key Takeaways: Powered by lumidawealth.com Investors have $7 trillion parked in cash funds, creating significant potential for a rally if Nvidia’s earnings report meets or exceeds expectations. Institutional exposure...

Read more

Cisco Raises Revenue Outlook After Posting Strong Q3 Results Driven by AI and Networking Demand

by Team Lumida
2 weeks ago
Cisco Raises Revenue Outlook After Posting Strong Q3 Results Driven by AI and Networking Demand

Key Takeaways: Powered by lumidawealth.com Cisco Systems increased its fiscal year revenue forecast to $56.5 billion–$56.7 billion, up from $56 billion–$56.5 billion, surpassing analyst expectations of $56.4 billion. Fiscal...

Read more

Siemens Exceeds Expectations with Strong Industrial Growth, Revenue Up 7%

by Team Lumida
2 weeks ago
Siemens Exceeds Expectations with Strong Industrial Growth, Revenue Up 7%

Key Takeaways: Powered by lumidawealth.com Siemens reported a 7% revenue increase to €19.76 billion for Q2, beating analyst expectations of €19.22 billion. Net profit rose to €2.25 billion, surpassing...

Read more

Sony Projects 13% Profit Decline Amid U.S. Tariff Impact Despite Strong Quarterly Earnings

by Team Lumida
3 weeks ago
black nikon dslr camera lens

Key Takeaways: Powered by lumidawealth.com Sony’s fourth-quarter net profit rose 4.6% year-over-year to ¥197.73 billion ($1.34 billion), beating analyst expectations, driven by strong performance in its music and movie...

Read more

TSMC April Sales Surge 48% as Firms Rush to Beat U.S. Tariffs

by Team Lumida
3 weeks ago
Taiwan Exports Surge 23.5% in June: AI Demand Fuels Massive Growth

Key Takeaways: Powered by lumidawealth.com Taiwan Semiconductor Manufacturing Co. (TSMC) reported a 48% year-over-year revenue increase in April, reaching NT$349.6 billion ($11.6 billion), surpassing analysts’ expectations of a 38%...

Read more

Puma’s Earnings Meet Estimates Amid Leadership Transition and Trade Uncertainty

by Team Lumida
3 weeks ago
white nike air force 1 low

Key Takeaways: Powered by lumidawealth.com Puma reported Q1 adjusted earnings of €76 million ($86 million) before interest and taxes, slightly ahead of analyst estimates but down from the previous...

Read more
Next Post

Cheniere Energy Q2 2024 Earnings Highlights: Exceeding Expectations and Raising Guidance

Datadog Q2 2024 Earnings Highlights: Solid Performance Driven by Enterprise Growth

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

China’s Economic Struggles: Factory Activity Falls Again

China’s Trade-War Pain Deepens as Exports Plunge and Jobs Are Hit

May 1, 2025
Geopolitical Forces Shape Oil Market Dynamics

Oil Prices Plunge as OPEC+ Announces Another Large Supply Hike

May 5, 2025

China’s Central Bank Adjusts Lending Tool, Signaling Shift Toward Looser Monetary Policy

March 25, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018